40
Participants
Start Date
March 1, 2022
Primary Completion Date
September 4, 2025
Study Completion Date
September 4, 2025
Atezolizumab
Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
Capecitabine
Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
Oxaliplatin
Oxaliplatin is administered by IV infusion on Day 1 of each 21 day cycle. Treatment for up to six cycles.
Tiragolumab
Tiragolumab is administered by IV infusion on Day 1 of each 21 day cycle.
The General Hospital of People?s Liberation Army (301 Hospital), Beijing
the First Hospital of Jilin University, Changchun
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing
Nan Tong Tumor Hospital, Nantong
The Second Affiliated Hospital of Anhui Medical University, Hefei
Affiliated Hopsital of Jining Medical University, Jining
The First Affiliated Hospital, Zhejiang University, Hangzhou
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou
First Affiliated Hospital of Gannan Medical University, Ganzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
The First Affiliated Hospital of Xian Jiao Tong University, Xi'an
Shanxi Province Cancer Hospital, Taiyuan
Hoffmann-La Roche
INDUSTRY